This review highlights significant advancements in antibody–drug conjugates (ADCs)
equipped with metal-based and nature-inspired payloads, focusing on synthetic strategies …

Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now
often treated in the newly diagnosed and relapsed and/or refractory settings with …

Background Multiple myeloma remains incurable, and heavily pretreated patients with
relapsed or refractory disease have few good treatment options. Belantamab mafodotin …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

In multiple myeloma impressive outcomes have improved with the introduction of new
therapeutic approaches, mainly those including naked monoclonal antibodies such as …

Simple Summary This paper deals with Belantamab mafodotin, a novel anti-BCMA antibody-
drug conjugate licensed by regulatory agencies for the treatment of anti-CD38-refractory …

Preclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf)
and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety …

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and
clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the …

To address the dearth of therapeutic options available for relapsed-refractory multiple
myeloma (RRMM), attention has shifted to immunotherapeutic strategies, with most products …

Simple Summary In newly diagnosed multiple myeloma patients (NDMM) the introduction of
three-drug, and recently, four-drug combinations allowed to reach response rates never …